The future of the global swine fever vaccine market looks promising with opportunities in the government tender and market sale markets.
- Within the type category, cell line origin is expected to witness higher growth over the forecast period due to because of increased uniformity and scalability in large-scale vaccine production.
- Within the application category, government tender is expected to witness higher growth over the forecast period due to because of large-scale government vaccination of livestock for the purpose of controlling national diseases.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to because of increased size of the swine population and more government control of diseases.
Emerging Trends in Swine Fever Vaccine Market
Through 2025 to 2027, we will see the shift from emergency vaccination to the control and management of swine fever vaccinations. We see African swine fever as the main driver for this market, while regulators see an increased need for clear distinctions among vaccines and diagnostics. Lucintel predicts that the adoption will follow the geography of the disease, the capacity of the manufacturers, and the product evidence.- Regionalization: The licensed African swine fever vaccine programs of Navetco's NAVETCO-ASFVAC in Vietnam show the endemic market providing its own supply. (2022-2025) Indonesia and the Philippines continue to assess local appropriate solutions. Regional production will increase due to the slow import response and the high cost of cold chains.
- Regulatory Evidence: Regulators are increasingly focused on DIVA, genetic stability, and field safety and so on before the widespread use. The European Food Safety Authority (EFSA) has already published several warnings for the unregulated use of vaccines which creates a negative impact on the surveillance system. Regulatory approval in the next three to five years will make an important difference for scalable products or emergency vaccines.
- Platform Diversification: Investigating vaccines beyond live-attenuated vaccines will include subunit, viral-vectored, DNA, and mRNA vaccines. There are several candidates for African swine fever vaccines that the U.S. Department of Agriculture has reported will be evaluated in 2024-2025. This may be safer and allow vaccines to adapt to different strains.
- Integrated Biosecurity: Some producers are bundling vaccine purchases with other aspects of herd-health programs, and are making decisions about movement, testing, and traceability together with vaccination. China reported 478.7 million pigs at the end of 2024. This integration will impact vaccine suppliers differently based on whether or not they provide evidence, training, and surveillance, in addition to the vaccine.
- Manufacturing Resilience: Due to repeated shocks from disease outbreaks, some producers and governments have implemented regional fill-finish and seed-stock controls as well as redundant supply chains. According to the World Organization for Animal Health, African Swine Fever is reported in over 70 countries and territories in their latest publications. Having additional production capacity in these regions will improve both timeliness and market access.
Recent Developments in the Swine Fever Vaccine Market
Swine fever vaccine market activity will build momentum from 2025 to 2027, following African swine fever (ASF) transition from a containment issue to a commercial issue. Lucintel identifies the Asia-Pacific region as the key demand region. Manufacturing scale, field evidence, and country approvals are now more important than lab evidence.- Regulatory Approvals: The January 2025 Philippines Department of Agriculture granting of commercial approval to AVAC ASF LIVE after field use in Vietnam, demonstrates 'pioneer field use' and provides an evidence standard for other countries to follow and remove farmer hesitancy for the next 3 to 5 years.
- Production Increases: The ASF vaccine producers, NAVETCO and AVAC, have both potential production for domestic stock and export. In 2024 Vietnam reported an annual production capacity of about 5 million doses. Open market supply will decrease price and make routine vaccination economical for smaller holdings.
- International Partnerships: The cooperation between Indonesian and Vietnamese authorities on ASF vaccine reviews for 2025 reflects the need for all of Southeast Asia to have regionally validated products. Cross border reviews will reduce approval time and create regional procurement for the next several years.”
- Technology Launches: In 2025, ASFV-G-ΔI177 and other gene-deleted live vaccines continued to be of priority in commercial development. Their ability to distinguish vaccinated from infected animals can aid surveillance and recuperation efforts to restore trade. However, commercial challenges are associated with cold-chain logistics.
- Government Procurement: For 2025, China continued large-scale ASF prevention programs that combined biosecurity, vaccine, and provincial surveillance research. Without a commercial ASF vaccine deployed across the country, government procurement and control of disease spending will continue to affect the design of vaccines, the manufacturing of vaccines, and the market for the next 3 years.
Strategic Growth Opportunities in the Swine Fever Vaccine Market
The swine fever vaccine market is now entering a new phase of its commercial stage as African swine fever continues to be endemic in many regions and as some governments develop preparedness. Between 2024 and 2026, more confidence in vaccines, tighter biosecurity budgets, and larger pork supply chains will result in an increase in demand beyond the emergency procurement level. Lucintel’s market perspective suggests that recurring vaccination programs will create a larger market than responding to outbreaks on a case by case basis.- Commercial Pig Production: Vaccines can be integrated into regular herd health programs, which can help increase consistency of market demand. 2025 saw the use of locally produced African swine fever vaccines by farms in Vietnam. Over the next 3 to 5 years, integrators will favor products with lower mortality rates and take less time to administer.
- Expanding Into New Markets: Improving veterinary infrastructure and increasing pork demand in many countries in Southeast Asia, Latin America, and certain countries in Africa will create opportunities for new distribution focused markets. The June 2025 domestic production of the Vietnamese African swine fever vaccine will serve as a good example and a strong incentive for neighboring countries to follow. The speed at which suppliers develop their market will depend on their partnerships to register locally.
- Premium Vaccine Platforms: Suppliers will finance vaccines that have stronger field evidence and cold chain stability with flexible dosing. In 2025, regulators continued evaluating modified-live African swine fever candidates, including products for safe deployment. Premium pricing will be introduced by suppliers on products that result in lower mortality and fewer disruptions to production.
- Diagnostics-linked Services: Vaccine producers can offer surveillance, strain identification, and post-vaccination monitoring in order to preserve efficacy. FAO and WOAH reported on African swine fever in 2025, reflecting ongoing data gaps. Retaining customers should be the goal with these types of services. Offering bundled services will show farmers that vaccination provides the protection of their herds.
- Contract Manufacturing: Producing locally reduces import delays and improves the flexibility of government procurement. South Korea approved an African swine fever vaccine candidate for field use in September 2025, demonstrating regulatory progress. In the next three to five years, local production will improve access while reducing the risk of supply.
Swine Fever Vaccine Market Drivers and Challenges
African swine fever and classical swine fever continue to disrupt pork production, stimulating the need for preemptive vaccination. The swine fever vaccine market is impacted by various factors such as technology, prevalence of livestock diseases, economic impacts, regulatory changes, sustainability, and manufacturing capacity. Lucintel considers these and other factors as the driving forces for the potential market expansion.The factors responsible for driving this market include:
- Increasing Outbreaks of Diseases: The outbreaks of African swine fever drive the need for reliable vaccines and vaccination systems. In January 2025, the WOAH continued to report outbreaks of the disease in multiple countries; thus, demonstrating the disease’s transboundary nature. The demand for prevention, surveillance, and immunization will continue to displace the reliance on the culling and movement of animals in the next 3 to 5 years.
- Improved Vaccine Technology: Advancements in vaccine technologies such as recombinant, subunit, vector-based, and attenuated technologies will improve vaccine safety, increase efficacy and reduce vaccine development times. For African swine fever, in 2025, ongoing research globally will progress multiple candidates to vaccines through containment animal studies."
- Regulatory and Governmental Assistance: Public organizations have an interest in funding diseases of concern, preparedness and research for control of swine fever as it impacts food security and rural livelihoods. In June 2025 the European Union sustained the implementation of coordinated surveillance and control of African swine fever in the affected member states In the next 3 to 5 years Public funding, regulatory approval harmonization, and national vaccination plans will significantly lower adoption bottlenecks and contribute to market development.
- Financial Support for Producers: When vaccines are available, swine fever might represent a trade barrier, animal loss and expenditures for the disposal and control of disease as a cost of doing business. In 2025, pig production world-wide was estimated at over 100 million tons, making production vulnerable to disease shocks. The next 3 to 5 years are expected to show a growing interest by producers in the cost of vaccination versus potential production losses, which will increase the overall market.
- Increasing Intensive Pig Farms: Rising pork consumption and the growing construction of larger, densely populated pig farms creates the need for organized herd health programs. In 2025, China continued to account for the bulk of pig production, affirming the need for disease control in high density farming. The next 3 to 5 years will see farm consolidation, biosecurity integration and veterinary management create stronger dynamics for vaccine uptake.
The challenges facing this market include:
- Uncertainty Concerning Both Regulations and Efficacy: Swine fever vaccines must demonstrate robust protection, while not causing diagnostic confusion or generating safety concerns or risks associated with live vaccine strains. In February 2025, regulatory authorities in some markets continued to require comprehensive safety and field-performance data prior to broader market approvals. In the next 3-5 years, lengthy approvals and different standards in different countries may result in even higher development costs and limited availability of vaccines across borders.
- Manufacturing and Distribution Challenges: Vaccine production on a larger scale requires specialized facilities, biological quality controls, and cold-chain logistics, as well as rapid delivery to outbreak zones. In 2025, many livestock health supply chains still experienced transport and input cost challenges, particularly in developing economies. In the next 3-5 years, process challenges and an unbalanced distribution network may restrict vaccine access in developed country markets, even with approvals.
- Challenges To Producer Acceptance and Operations: The duration of protection and side effects are a concern, as is the potential for increased workload and uncertainty regarding market access. In 2025, many disease control programs continued to rely on surveillance, biosecurity, and culling, and vaccination was done on a limited scale. In the next 3-5 years, a lack of awareness, variable Veterinary services and gaps in compensation may slow the adoption of vaccines, especially among smallholder farmers.
List of Swine Fever Vaccine Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies swine fever vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the swine fever vaccine market companies profiled in this report include:
- WINSUN
- CAHIC
- Merial
- MSD Animal Health
- Chopper Biology
- Ceva
- ChengDu Tecbond
- Veterinary
- Ringpu Biology
- Qilu Animal
Swine Fever Vaccine Market by Segment
The study includes a forecast for the global swine fever vaccine market by type, application, and region.Type [Value ($M) from 2019 to 2035]:
- Tissue Culture Origin
- Cell Line Origin
Application [Value ($M) from 2019 to 2035]:
- Government Tender
- Market Sales
- Others
Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Swine Fever Vaccine Market
The market for swine fever vaccines is shifting away from emergency preparedness and moving towards regulated, country-specific programs. From 2025 to 2027, governments plan to focus on African swine fever (ASF) surveillance, vaccine validation, and regional vaccine manufacturing, while classical swine fever vaccination is embedded in well-defined control systems. Based on Lucintel’s most recent market analysis, policy implementation and approval will dominate over major research activities.- United States: In the absence of a licensed swine fever vaccine, the primary response in the U.S. is focused on Federal preparedness and foreign animal disease (FAD) research. The USDA APHIS allocated $17.5 million for African swine fever (ASF) prevention and preparedness for FY2025 (September 2025). Until a swine fever vaccine is approved and shown safe and effective in the U.S., demand will remain for diagnostics, containment, and imports that have been validated.
- China: China implements mandatory classical swine fever vaccination, an intensive surveillance program for ASF, and a national animal disease control program for 2025 covering more than 450 million pigs. With an extremely large domestic pig population and a centralized system of veterinary oversight, China will be a large market for vaccine manufacturing and will help advance the evaluation of new ASF vaccine candidates.”
- Germany: Under the directives of the EU, German federal states controlled ASF and developed programs to vaccinate against classical swine fever as part of their overall control strategy. In 2025, Germany had two outbreaks of ASF in domestic pigs (December 2025). Regional controls will sustain the market for approved vaccines, biosecurity products, and stockpiling. The approval of the EU is however, crucial.
- India: During 2025 (April), ICAR and Indian Biologics continued the development and scale-up of ASF and classical swine fever vaccines. India’s Ministry of Fisheries, Animal Husbandry and Dairying funded disease surveillance of 28 states during this time. Public sector research along with the dispersed nature and the increasing popularity of pig farming will influence which locally manufactured vaccines gain market acceptance.
- Japan: During 2025 (October), the Ministry of Agriculture maintained the policy of classical swine fever vaccination and surveillance in all 47 prefectures of Japan. Japan will sustain an important demand for all approved products as well as reinforce its strict import policies and disease control.
Features of the Global Swine Fever Vaccine Market
- Market Size Estimates: swine fever vaccine market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: swine fever vaccine market size by type, application, and region in terms of value ($B).
- Regional Analysis: swine fever vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the swine fever vaccine market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the swine fever vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the swine fever vaccine market by type (tissue culture origin and cell line origin), application (government tender, market sales, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- WINSUN
- CAHIC
- Merial
- MSD Animal Health
- Chopper Biology
- Ceva
- ChengDu Tecbond
- Veterinary
- Ringpu Biology
- Qilu Animal
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

